Teva’s Ajovy & Pfizer’s Vizimpro Get EU Thumbs Up From CHMP

The European Medicines Agency’s drug evaluation committee has recommended for approval Teva’s Ajovy for migraine and Pfizer’s Vizimpro for NSCLC, as well as two more biosimilar versions of adalimumab (AbbVie’s Humira) and generics of atazanavir and feboxustat.

Recommendation — The CHMP has recommended six new medicines for approval in the EU. • Source: Shutterstock

Teva Pharmaceutical Industries Ltd.’s injectable migraine prevention drug Ajovy (fremanezumab) was one of six new products to win a recommendation for EU marketing authorization from the European Medicines Agency’s drug evaluation committee (CHMP) at its January meeting last week.

Ajovy was one of only two products containing a new active substance to get a positive opinion from the CHMP:...